FeesSafety
Pluang+

DeFi Development tokenizes CHAD preferred stock for onchain trading on Solana and other blockchains.

Company Fundamentals
11 Nov 2026, 23:00 WIB
GlobeNewsWire
View Source
Bullish
DeFi Development tokenizes CHAD preferred stock for onchain trading on Solana and other blockchains.

DeFi Development Corp. has tokenized its Variable Rate Series C Perpetual Preferred Stock (CHAD) in partnership with xStocks, creating CHADx, a 1:1 tokenized version available on Solana and nine other blockchains. This innovation allows investors to hold and trade CHADx onchain, providing easier access beyond traditional brokerage accounts and outside regular market hours. CHADx reflects daily dividends automatically in token balances, although it does not confer ownership rights of the underlying shares. This move expands access to digital credit products and aligns with DeFi Development's strategy to integrate public assets with onchain finance, leveraging Solana's ecosystem.

DeFi Development Corp.'s tokenized CHAD preferred stock is introduced as context for market activity. For readers following US stocks on Pluang, here is the market snapshot as of Nov 12, 2026 03:31 WIB: out of 150 priced US stocks, 96 rose and 52 fell today. Notable movers include MRVL at USD 169.34 with a 1-day change of +9.69% and a Pluang order activity split of 53% Sell / 47% Buy, IQ at USD 0.96 with +8.83% change and 42% Sell / 58% Buy, and INTC at USD 62.60 with +7.69% change and 24% Sell / 76% Buy. Typical hold times range from 46 to 116 days on Pluang.

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
2 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Lakefront Biotherapeutics posts Q3 2026 profit, advances autoimmune drug gamgertamig, plans €50M share buyback

Lakefront Biotherapeutics posts Q3 2026 profit, advances autoimmune drug gamgertamig, plans €50M share buyback

Lakefront Biotherapeutics reported a net profit of €13.9 million for the first nine months of 2026, a significant turnaround from a €461.3 million loss in the same period last year. The company highlighted progress with its autoimmune drug gamgertami...

Company Fundamentals
Bullish
5 hours ago
Olin declares $0.20 quarterly dividend, marking 100 years of consecutive payments.

Olin declares $0.20 quarterly dividend, marking 100 years of consecutive payments.

Olin Corporation announced a quarterly dividend of $0.20 per share, celebrating 100 years and 400 consecutive quarterly dividend payments. This milestone highlights Olin's long-term financial strength and commitment to shareholder value through vario...

Company Fundamentals
Bullish
5 hours ago
Gold prices dip below $4,000 amid inflation fears and Fed rate hike expectations.

Gold prices dip below $4,000 amid inflation fears and Fed rate hike expectations.

Gold prices have fallen below the key $4,000-an-ounce level due to persistent inflation and expectations that the Federal Reserve will continue raising interest rates. After holding support around $4,000 for two weeks, gold dropped to $3,987 an ounce...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App